TVGN - Tevogen Bio Holdings, Inc. Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Tevogen Bio Holdings (TVGN) develops innovative T-cell based treatments for cancer and viral pathologies, leveraging its own intellectual property. This market valuation on the GURU.Markets platform is currently fixed at 0.00, linking business potential with ethical compliance and an environmentally conscious approach to laboratory research. However, the lack of revenue and reliance on new equity issuances create significant financial risks in the event of potential trial failures.
Tevogen Bio Holdings, Inc. - analytical breakdowns and key metrics (TVGN)
- stock price and consensus target price:
- market capitalization statistics:
- book value of equity indicators:
- debt and liquidity data:
Debt to Equity Tevogen Bio Holdings|TVGN - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Tevogen Bio Holdings, Inc.|TVGN - Aggregate Debt Obligations|Debts to Book Capitalization Tevogen Bio Holdings|TVGN - Company Long-Term Debt|Company Short-Term Debts Tevogen Bio|Quick Liquidity tevogen.com
- financial results and valuation multiples details:
TVGN - Company Net Income|Future Profit Tevogen Bio Holdings|TVGN - Company Value to Net Income|Forward P/E Multiple Tevogen Bio|TVGN - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tevogen Bio Inc.|TVGN - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Tevogen Bio|TVGN - Earnings per share for the last twelve months|Quarterly EPS earnings growth tevogen.com|TVGN - Earnings per share growth this year|Earnings growth forecast for next year Tevogen Bio Holdings
- revenue and sales proceeds data:
Summary company analysis:Tevogen Bio Holdings TVGN
EV/EBITDA serves as a fundamental business valuation tool that eliminates the impact of debt load and tax regimes. By analyzing EV/EBITDA valuation trends, an investor compares the total enterprise value with its operating profit before depreciation and amortization. This metric determines the payback period of assets, stripped of financial manipulations. For Tevogen Bio (TVGN), this indicator is critical during the platform commercialization stage when seeking strategic partners and raising capital.
Who Tevogen Bio Holdings competes with
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Inc BIIB|EV/EBITDA Multiple neurocrine.com NBIX|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Axsome|ACAD: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation XENE|VKTX (Viking Therapeutics Corp) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharma (CPRX)|DNLI (Denali Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Harmony Pharma - Enterprise Value to EBITDA Ratio|BHVN: Enterprise Value to Operating Income Before Depreciation|Amylyx Pharmaceuticals - EV/EBITDA Multiple|Company Value to EBITDA trevitherapeutics.com|PRAX: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio AVXL (Anavex Life Sciences Corp.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell, Inc.|Company Value to EBITDA Prothena Biosciences PRTA|Enterprise Value to EBITDA Ratio ALEC (Alector Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio Annexon, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros Corporation OMER|NGNE - Enterprise Value to EBITDA Ratio|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VYGR|NMRA: EV/EBITDA Multiple|Scilex Holding Company - Business Value to Operating Income Before Depreciation|ACOG (Alpha Cognition Corp) - EV/EBITDA Multiple|Cognition Therapeutics, Inc. - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple IKT|SAVA (Cassava) - Business Value to Operating Income Before Depreciation|Assertio Holdings, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation COYA|VistaGen Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Ovid Therapeutics OVID|ABOS: EV/EBITDA Multiple|CervoMed Corporation (CRVO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alterity Therapeutics Limited|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CLNN|EV/EBITDA Multiple PEPG|JUNS (Jupiter Neurosciences) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Corp RLMD|EV/EBITDA Multiple Annovis Bio Corporation ANVS|gracetx.com - EV/EBITDA Multiple|Firefly Neuroscience, Inc (AIFF) - Enterprise Value to EBITDA Ratio|Klotho Neurosciences (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NeuroSense Therapeutics, Ltd. - Business Value to Operating Income Before Depreciation|RVPH (Reviva Pharmaceuticals Holdings) - EV/EBITDA Multiple|MetaVia Inc (MTVA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NRXS|Total Company Value to Operating Income Before Depreciation Ratio Helius Medical Technologies Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization passagebio.com PASG|NEUP: Enterprise Value to Operating Income Before Depreciation|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Athira - Enterprise Value to Operating Income Before Depreciation Ratio|ADXN: EV/EBITDA Multiple|ALZN (Alzamend Neuro, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|PTIX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple KTTA|Enterprise Value to Operating Income Before Depreciation Ratio CRGT|Avenue Therapeutics Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BCLI|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CHRO (Chromocell Therapeutics Corp)|ELYM: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ITCI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharmaceuticals Inc|marinuspharma.com (MRNS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|NRBO - Company Value to EBITDA|EV/EBITDA Multiple SAGE (Sage Therapeutics, Inc)|SNPX: Enterprise Value to Operating Income Before Depreciation|Trevena Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio vigilneuro.com VIGL|WENA: EV/EBITDA Multiple|Company Value to EBITDA Cerevel Therapeutics Inc (CERE)
